Scalper1 News
Drug giant and IBD 50 stock Allergan (AGN) modestly beat analysts’ Q2 consensus Thursday, but it put off guidance for another month as it sorts through the impact of recent M&A. Allergan’s earnings, excluding one-time items, rose 29% from the year-earlier quarter to $4.41 a share, beating analysts’ consensus by 3 cents, according to Thomson Reuters. Revenue jumped 116% to $5.76 billion, or $5.73 billion excluding divested Western European assets, Scalper1 News
Scalper1 News